Paper · 41517844
Epidemiology of Gastric Cancer in Korea (1999-2022): Incidence, Survival, and 5-Year Conditional Relative Survival.
Park KB and 7 others. J Gastric Cancer, 2026. Cited by 5 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Epidemiology of Gastric Cancer in Korea (1999-2022): Incidence, Survival, and 5-Year Conditional Relative Survival. Papers, record 41517844. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41517844
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Epidemiology of Gastric Cancer in Korea (1999-2022): Incidence, Survival, and 5-Year Conditional Relative Survival.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Stomach Neoplasms | Major topic |
| Humans | |
| Incidence | |
| Republic of Korea | |
| Female | |
| Male | |
| Aged | |
| Registries | |
| Survival Rate | |
| Middle Aged | |
| Aged, 80 and over | |
| Adult |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| National Cancer Center Foundation | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38,225,769 | Risk Factors of Gastric Cancer and Lifestyle Modification for Prevention. | J Gastric Cancer | 2024 | https://conductscience.org/library/papers/38225769 | PubMed |
| 2 | 36,959,359 | Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. | Nat Rev Clin Oncol | 2023 | https://conductscience.org/library/papers/36959359 | PubMed |
| 3 | 38,572,751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 4 | 31,028,082 | Different Patterns of Conditional Survival of Breast Cancer Patients by Age and Histologic Types: Evidence from the Korean Nationwide Registry. | Cancer Epidemiol Biomarkers Prev | 2019 | https://conductscience.org/library/papers/31028082 | PubMed |
| 5 | 39,822,171 | Korean Gastric Cancer Association-Led Nationwide Survey on Surgically Treated Gastric Cancers in 2023. | J Gastric Cancer | 2025 | https://conductscience.org/library/papers/39822171 | PubMed |
| 6 | 35,471,731 | Adherence to guidelines at the patient- and hospital-levels is associated with improved overall survival in patients with gastric cancer. | J Surg Oncol | 2022 | https://conductscience.org/library/papers/35471731 | PubMed |
| 7 | 39,822,170 | Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline). | J Gastric Cancer | 2025 | https://conductscience.org/library/papers/39822170 | PubMed |
| 8 | 25,061,536 | Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. | J Gastric Cancer | 2014 | https://conductscience.org/library/papers/25061536 | PubMed |
| 9 | 28,448,662 | Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. | JAMA Oncol | 2017 | https://conductscience.org/library/papers/28448662 | PubMed |
| 10 | 41,093,777 | Conditional Relative Survival Among Patients With Gastric Cancer Undergoing Surgery: A Hospital-Based Cohort Study. | J Gastric Cancer | 2025 | https://conductscience.org/library/papers/41093777 | PubMed |
1 to 10 of 34
See all 34 referencesCited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,845,259 | The CALLY Index for Unresectable or Recurrent Gastric Cancer Treated With Nivolumab: A Multicenter Retrospective Study. | J Gastric Cancer | 2026 | https://conductscience.org/library/papers/42845259 | PubMed |
| 42,590,138 | Comparative Analysis of Short- and Long-Term Surgical Outcomes Following Open Conversion from Laparoscopic and Robotic Gastrectomy in Patients with Gastric Cancer. | J Clin Med | 2026 | https://conductscience.org/library/papers/42590138 | PubMed |
| 42,226,414 | Excess mortality from gastric cancer in Korea during the COVID-19 pandemic, 2020-2023. | Epidemiol Health | 2026 | https://conductscience.org/library/papers/42226414 | PubMed |
| 41,517,843 | Journal of Gastric Cancer's Ascent and the Enduring Contributions of Dr. Keun Won Ryu. | J Gastric Cancer | 2026 | https://conductscience.org/library/papers/41517843 | PubMed |
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41517844
GET https://conductscience.org/api/papers/v1/41517844/references?page=2